University Hospital of Heidelberg - medical department V
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldschmidt, Hartmut
NCT06216158: Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Recruiting
3
411
Europe
Iberdomide, Isatuximab, Sarclisa, Dexamethasone
University of Heidelberg Medical Center, KKS Netzwerk, Wuerzburg University Hospital, Sanofi, Bristol-Myers Squibb
Multiple Myeloma
12/28
06/29
GMMG-HD7, NCT03617731 / 2017-004768-37: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Calendar Jan 2025 - Dec 2025: From GMMG HD7 trial for newly diagnosed multiple myeloma
Jan 2024 - Dec 2024: Submission for newly diagnosed multiple myeloma (transplant eligible)
Hourglass Oct 2021 - Dec 2021 : From first part of trial in newly diagnosed multiple myeloma
Active, not recruiting
3
662
Europe
Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Isatuximab
University of Heidelberg Medical Center
Multiple Myeloma
05/25
12/25
NCT05804032 / 2022-000996-38: Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
514
Europe
Isatuximab, Sarclisa, Lenalidomide, Bortezomib, Velcade, Dexamethasone
University of Heidelberg Medical Center, Deutsche Studiengruppe Multiples Myelom (DSMM), KKS Netzwerk, Sanofi
Multiple Myeloma
07/25
07/26

Download Options